follow recent bullish kol comment ad topic rux increas
pt reiter overweight rate model us atop dermat
vitiligo launch respect combin global sale surpass
late importantli believ fulli capabl launch
topic rux indic specialti sale forc coupl hundr peopl
increas sg spend modestli out-year off-set
addit revenu durabl beyond jakafi com patent
expir bottom line believ like captur maximum
valu launch product argument enhanc
recent posit vitiligo data believ adopt easi given strong
efficaci well-known differenti mechan
kol refer topic jak inhibit sexi next panacea
dermatolog host medic dermatolog panel recent nyc kol day
discuss kol bullish topic rux atop dermat ad
state patient receiv topic treatment product includ
eucrisa protopic/tacrolimu steroid see signific benefit
non-steroid treatment vitiligo view topic rux interest robust
opportun sinc noth includ steroid work exclaim anyon
vitiligo scream topic rux upon approv
unlik steroid topic rux effect indic ad kol believ
efficaci topic rux compar triamcinolon exce
current avail non-steroid also note eucrisa protop burn
topic rux note compani launch phase trial data
expect vitiligo recal announc posit phase ii result
recent call full data present later year compani
plan launch phase trial data expect
topic rux could produc combin global sale us
approxim patient diagnos ad vast major
mild moder diseas assum phase success anticip us commerci
launch model conserv patient penetr result sale
late vitiligo approxim patient us
assum us launch like ad model moder penetr result sale
approach late though launch vitiligo may occur
year ad kol believ off-label use signific among approv
first indic given broad applic like anti-tnf
commerci clinic risk jakafi/ruxo olumiant/bari pemi topic rux
leader develop drug myelodysplast syndrom oncolog
dcf includ jakafi
sales/jakavi royalti pemigatinib sale
cholangio topic rux sale atop derm
royalti capmatinib royalti
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
ad patient
diagnos ad patient
mild/moder ad patient
mild/moder ad patient use topic treatment
ww sale
ww sale
vitiligo patient
vitiligo patient seek treatment
ww sale
ww sale
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
data brave brave ii phase trial
data phase ii continu dose cohort
nsclc exon mutat
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
product sale
product sale
product sale
product sale
total revenu
royalti revenu
royalti revenu
royalti revenu
total revenu
good sold
revenu
revenu
revenu
expens relat note convers
revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
good sold
revenu
revenu
revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
